ICON plc a leading global healthcare intelligence and clinical research organization, has received multiple prestigious awards in the second half of 2024, further solidifying its position as a top performer in the clinical research industry. For the second consecutive year,…
Colorectal Cancer Breakthrough: Bristol Myers Squibb Secures EC Approval for Opdivo + Yervoy in MSI-High mCRC Bristol Myers Squibb has announced that the Colorectal Cancer European Commission (EC) has approved the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) as the…
Gilead Sciences, Inc and Terray Therapeutics, Inc. have entered into a strategic collaboration aimed at discovering and developing novel small molecule therapies across multiple therapeutic targets. This partnership leverages Terray’s cutting-edge tNova platform to accelerate drug discovery and deliver innovative…
Grifols, a global healthcare leader and prominent manufacturer of plasma-derived medicines, has achieved the distinction of being ranked the number one biotechnology company in the S&P Dow Jones Sustainability Indices (DJSI). This marks the company’s fifth consecutive year in the…
UCB has announced results from the ORCHESTRA proof-of-concept study evaluating minzasolmin, an investigational oral small molecule developed in collaboration with Novartis to inhibit alpha-synuclein misfolding in early-stage Parkinson’s disease. Unfortunately, the study did not meet its primary and secondary clinical…
AbbVie has announced a definitive agreement to acquire Nimble Therapeutics, a biotech company specializing in the discovery and development of innovative oral peptide therapies. This acquisition includes Nimble’s lead investigational oral peptide IL23R inhibitor, currently in preclinical development for psoriasis…
Merck known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional approval of WELIREG® (belzutifan), an oral hypoxia-inducible factor-2…
Pfizer and Alliance Foundation Trials, LLC (AFT) recently unveiled findings from the Phase 3 PATINA trial, highlighting the potential of IBRANCE (palbociclib) in improving outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast…
Cyrus Biotechnology, Inc. has announced new data demonstrating the potent activity of its engineered IgG-degrading enzyme, CYR241, in a rabbit redosing model. Importantly, the study revealed that CYR241 does not induce anti-drug antibodies (ADAs) after repeat administrations at therapeutic doses,…
Menarini Group, Stemline Therapeutics, and MEDSIR have presented groundbreaking research on the ADELA clinical trial, which targets therapeutic resistance in advanced ER+/HER2- breast cancer. This research was shared at the San Antonio Breast Cancer Symposium 2024 (SABCS). ADELA is a…
Sirius Therapeutics has announced promising preliminary results from its Phase 1 first-in-human clinical trial of SRSD107, a next-generation siRNA therapeutic under development for the prevention and treatment of thromboembolic disorders. These include conditions such as myocardial infarction, ischemic stroke, and…
SK pharmteco, a global leader in contract development, manufacturing, and analytical testing services for the pharmaceutical and cell & gene therapy industries, has announced a groundbreaking brand unification initiative. This strategic effort consolidates the expertise and capabilities of several renowned…